 |
Publisher: Peytchinski Publishing
ISSN: 1312-773X (Online)
Issue: 2018, vol. 24, issue1
Subject Area: Medicine
-
DOI: 10.5272/jimab.2018241.1936
Published online: 22 March 2018
Review article
J of IMAB. 2018 Jan-Mar;24(1):1936-1940
MAY GLYPICAN-3 BE A NOVEL BIOMARKER AND POTENTIAL THERAPEUTIC TARGET IN HEPATOCELLULAR CANCER?
Irina I. Ivanova
,
Clinic of Gastroenterology, Department of Internal Diseases, Medical University – Varna, Bulgaria.
ABSTRACT:
The burden of advanced chronic liver disease is increasing worldwide, despite the recent advances in the management of chronic hepatitis viral infections. The abdominal ultrasound is the only approved method for surveillance of patients with cirrhosis, a premalignant condition for hepatocellular cancer (HCC). Although alpha fetoprotein has been known as a tumour marker for HCC, it is not commonly used for screening due to suboptimal sensitivity and specificity. There is a need to introduce a novel biomarker for definition of HCC in early stage and for prognostic and therapeutic response assessment. A review of the current evidences, encouraging the use of glypican-3 in management of patients with cirrhosis and HCC is presented.
Keywords: hepatocellular carcinoma, cirrhosis, biomarkers, glypican-3,
- Download FULL TEXT /PDF 534 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Ivanova II. May Glypican-3 be a novel biomarker and potential therapeutic target in hepatocellular cancer? J of IMAB. 2018 Jan-Mar;24(1):1936-1940. DOI: 10.5272/jimab.2018241.1936
Correspondence to: Irina Ivanova Ivanova, Clinic of Gastroenterology, UMHAT “St. Marina”, 1, Hristo Smirnenski blvd., 9010 Varna, Bulgaria; E-mail: irina.ivanova@mu-varna.bg,
REFERENCES:
1. Kojiro M, Wanless IR, Alves V, Badve S, Balabaud C, Bedossa P, et al. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology. 2009 Feb;49(2):658-64. [PubMed] [CrossRef]
2. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004 Nov;127(5 Suppl 1):S35-50. [PubMed] [CrossRef]
3. Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, et al. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). Hepatology. 2015 Feb;62(3):737–50. [PubMed] [CrossRef]
4. Bruix J, Reig M, Sherman M. Evidence-Based Diagnosis, Staging, and Treatment of Patients with Hepatocellular Carcinoma. Gastroenterology. 2016 Apr;150(4):836–53. [PubMed] [CrossRef]
5. Llovet JM, Ducreux M, Lencioni R, Di Bisceglie AM, Galle PR, Dufour JF, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012 Apr;56(4):908-43. [PubMed] [CrossRef]
6. Bolondi L, Cillo U, Colombo M, Craxi A, Farinati F, Giannini EG, et al. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis. 2013 Sep;45(9):712-23. [PubMed] [CrossRef]
7. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-380. [PubMed] [CrossRef]
8. Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008 Jan;47(1):97-104. [PubMed] [CrossRef]
9. Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol. 2016 Jan;22(1):275-83. [PubMed] [CrossRef]
10. Filmus J, Capurro M. Glypican-3: A marker and a therapeutic target in hepatocellular carcinoma. FEBS J. 2013 May;280(10):2471–6. [PubMed] [CrossRef]
11. Cheng W, Huang PC, Chao HM, Jeng YM, Hsu HC, Pan HW, et al. Glypican-3 induces oncogenicity by preventing IGF-1R degradation, a process that can be blocked by Grb10. Oncotarget. 2017 Jul 6;8(46):80429-42. [PubMed] [CrossRef]
12. Wu Y, Liu H, Ding H. GPC-3 in hepatocellular carcinoma: current perspectives. J Hepatocell Carcinoma. 2016 Nov 8;3:63-67. [PubMed] [CrossRef]
13. Hsu HC, Cheng W, Lai PL. Cloning and expression of a developmentally regulated transcript MXR7 in hepatocellular carcinoma: biological significance and temporospatial distribution. Cancer Res. 1997 Nov;57(22):5179-84. [PubMed]
14. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003 Jul;125(1):89-97. [PubMed]
15. Xiao WK, Qi CY, Chen D, Li SQ, Fu SJ, Peng BG, et al. Prognostic significance of glypican-3 in hepatocellular carcinoma: a meta-analysis. BMC Cancer. 2014 Feb;14:104. [PubMed] [CrossRef]
16. Anatelli F, Chuang S-T, Yang XJ, Wang HL. Value of glypican 3 immunostaining in the diagnosis of hepatocellular carcinoma on needle biopsy. Am J Clin Pathol. 2008 Aug;130(2):219-23. [PubMed] [CrossRef]
17. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol. 2009 Mar;34(3):649-56. [PubMed]
18. Liu H, Li P, Zhai Y, Qu C-F, Zhang L-J, Tan Y-F, et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol. 2010 Sep;16(35):4410-5. [PubMed]
19. Zhang L, Liu H, Sun L, Li N, Ding H, Zheng J. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: A tissue microarray-based study. Acta Histochem. 2012 Oct;114(6):547-52. [PubMed] [CrossRef]
20. Chen IP, Ariizumi S, Nakano M, Yamamoto M. Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. J Gastroenterol. 2014 Jan;49(1):117-25. [PubMed] [CrossRef]
21. Sideras K, Bots SJ, Biermann K, Sprengers D, Polak WG, IJzermans JNM, et al. Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area. Br J Cancer. 2015 Jun;112(12):1911–20. [PubMed] [CrossRef]
22. Cui X, Li Z, Gao PJ, Gao J, Zhu JY. Prognostic value of glypican-3 in patients with HBV-associated hepatocellular carcinoma after liver transplantation. Hepatobiliary Pancreat Dis Int. 2015 Apr;14(2):157-63. [PubMed] [CrossRef]
23. Kaseb AO, Hassan M, Lacin S, Abdel-Wahab R, Amin HM, Shalaby A, et al. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016 Oct;7(43):69916-69926. [PubMed] [CrossRef]
24. Jeon Y, Kim H, Jang ES, Hong S, Kim JW, Yoon YS, et al. Expression profile and prognostic value of glypican-3 in post-operative South Korean hepatocellular carcinoma patients. APMIS. 2016 Mar;124(3):208-15. [PubMed] [CrossRef]
25. Ofuji K, Saito K, Suzuki S, Shimomura M, Shirakawa H, Nobuoka D, et al. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. Oncotarget. 2017 Jun;8(23):37835-44. [PubMed] [CrossRef]
26. Sun B, Huang Z, Wang B, Yu Y, Lin S, Luo L, et al. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis. Med Sci Monit. 2017;Feb;23:850–5. [PubMed]
27. Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012 Oct;23 Suppl 7:vii41-8. [PubMed] [CrossRef]
28. Liu JW, Zuo XL, Wang S. Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis. Eur Rev Med Pharmacol Sci. 2015 Oct;19(19):3655-73. [PubMed]
29. Wang YY, Zhou CJ, Li J, Zhou L, Li MS, Xiao B. [Value of detection of serum glypican-3 level in diagnosis and therapeutic effect evaluation of primary hepatocellular carcinoma]. [in Chinese] Nan Fang Yi Ke Da Xue Xue Bao. 2017 Aug;37(8):1060-5. [PubMed]
30. Ataide EC, Perales SR, Silva MG, Filho FC, Sparapani AC, Latuf Filho PF, et al. Immunoexpression of Heat Shock Protein 70, Glypican 3, Glutamine Synthetase, and Beta-Catenin in Hepatocellular Carcinoma After Liver Transplantation: Association Between Positive Glypican 3 and Beta-Catenin with the Presence of Larger Nodules. Transplant Proc. 2017 May;49(4):858-862. [PubMed] [CrossRef]
31. Haruyama Y, Yorita K, Yamaguchi T, Kitajima S, Amano J, Ohtomo T, et al. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J cancer. 2015 Oct;137(7):1643-51. [PubMed] [CrossRef]
32. Li J, Gao JZ, Du JL, Wei LX. Prognostic and clinicopathological significance of glypican-3 overexpression in hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2014 May;20(20):6336-44. . [PubMed] [CrossRef]
33. Feng J, Chen J, Zhu R, Yu L, Zhang Y, Feng D, et al. Prediction of early recurrence of hepatocellular carcinoma within the Milan criteria after radical resection. Oncotarget. 2017 Sep 8; 8(38): 63299-310. [PubMed] [CrossRef].
Received: 08 January 2018
Published online: 22 March 2018